UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2013 (January 8, 2013)

REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

New York	000-19034	13-3444607
(State or other jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)

(914) 847-7000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On January 8, 2013, at the J.P. Morgan Healthcare Conference in San Francisco, California, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., is providing a corporate update. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., at the J.P. Morgan Healthcare Conference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2013

REGENERON PHARMACEUTICALS, INC.

By: /s/ Joseph J. LaRosa
Name: Joseph J. LaRosa
Title: Senior Vice President, General Counsel and Secretary

Exhibit Index

Number	Description
99.1	Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., at the J.P. Morgan Healthcare Conference.

Exhibit 99.1

REGENERON

science to medicine™

J.P. Morgan Healthcare Conference
January 2013

SAFE HARBOR STATEMENT

Except for historical information, the matters contained in this presentation may constitute forward-looking statements that involve risks and uncertainties, including risks and uncertainties related to product development and clinical trials, unforeseen safety issues resulting from the administration of products and product candidates in patients, uncertainties related to the need for regulatory and other government approvals, government regulations, risks related to third party patents and proprietary technology, litigation, the need for additional capital, uncertainty of market acceptance of Regeneron's products and product candidates, the ability of the Company to meet any of its sales or other financial projections, the receipt of future payments, the continuation of business partnerships, and additional risks detailed from time to time in Regeneron's filings with the Securities and Exchange Commission (SEC). Please refer to Regeneron's Form 10-K for the year ended December 31, 2011 and its Form 10-Q for the quarter ended September 30, 2012 for additional information on these risks and uncertainties and for other information related to our business.

Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Regeneron. Regeneron is providing this information as of the original date of this presentation and expressly disclaims any duty to update any information contained in these materials, including without limitation any sales forecasts and any other forward-looking statements.


REGENERON Transformed
ZALTRAP
EYLEA
(aflibercept) Injection
For Intravitreal Injection
2 mg/0.05 mL
Single-use Vial
Arcalyst
(rilonacept)
3
REGENERON

REGENERON TRANSFORMED

EYLEA® LAUNCH HAS EXCEEDED EXPECTATIONS

One of the top 5 biopharmaceutical launches of all time

MULTIPLE REGULATORY APPROVALS

EYLEA US, EU, Japan, Australia, and other countries; ZALTRAP US

FOUR FULL QUARTERS OF PROFITABILITY

GAAP & Non-GAAP

STRONG FINANCIAL POSITION

Year end cash and receivables of ~$1.2B

WORLD'S #1 BIOPHARMACEUTICAL EMPLOYER

Science magazine annual poll; "Biotechnology Company of the Year" by Scrip Intelligence

REGENERON LOOKING FORWARD



EYLEA® (aflibercept) Injection For Intravitreal Injection

EXCEEDING EXPECTATIONS



U.S. LAUNCH

EYLEA net product sales of $276 million in 4Q12*

$838 million in full year 2012*

2013 EYLEA U.S. net sales guidance: ~50% growth (i.e. ~$1.2B to $1.3B)

* 4Q12 Sales Estimate

EYLEA® (aflibercept) Injection For Intravitreal Injection

EXPANDING BRANDED MARKET



* 4Q12 Sales Estimate

REGENERON

EYLEA® (aflibercept) Injection For Intravitreal Injection

EXPANDING GEOGRAPHY



Santen

Bayer REGENERON

EYLEA® (aflibercept) Injection For Intravitreal Injection

BROADENING INDICATIONS

Diabetic Macular Edema (DME)

Trials fully enrolled

Branch Retinal Vein Occlusion (BRVO)

Trial enrolling

Myopic CNV

Trial fully enrolled in Asia

Central Retinal Vein Occlusion (CRVO)

Approved in U.S.; Filings globally

EYLEA® (aflibercept) Injection For Intravitreal Injection

SECURING THE FUTURE

Novel Targets in Development for Retinal Disease

PDGFR

High affinity, fully-human antibody to PDGFR

Goal to enter clinic with co-formulated product in 2H13

ANG2

High affinity, fully human antibody to ang2

Goal to enter into ophthalmology clinical development in 2013

Novel formulation and delivery of EYLEA as well as evaluation of new technologies

ZALTRAP®
(ziv-aflibercept)
Injection for Intravenous Infusion

OPPORTUNITIES IN CANCER

ZALTRAP is the only agent that has demonstrated a statistically significant improvement in overall survival in combination with FOLFIRI versus FOLFIRI alone in patients who progressed on a prior oxaliplatin-containing regimen.

Approved in the US

Approved and launched in U.S.

Discovered by Regeneron and co-developed with Sanofi

Regeneron has worldwide co-commercialization rights

Pending Approval in the EU

Positive recommendation for approval by European CHMP

EU approval expected 1Q13

Regeneron has worldwide co-commercialization rights

EXPANDING LATE STAGE PIPELINE

REGN727

3 Phase

PCSK9 antibody for elevated cholesterol

Sarilumab

3 Phase

IL6R antibody for rheumatoid arthritis

REGN668

2 Phase

IL4R antibody for Asthma and Atopic Dermatitis

PCSK9: BLOCKING PCSK9 CAN POTENTIALLY LOWER LDL-C LEVELS[1-5]



(1) Tibolla G et al. Nutr Metab Cardiovasc Dis 2011;21:835-43. (2) Akram ON et al. Arterioscler Thromb Vasc Biol 2010;30:1279-81. (3) Duff CJ et al. Expert Opin Ther Targets 2011;15:157-68. (4) Horton JD et al. J Lipid Res 2009;50 Suppl:S172-7. (5) Cariou B et al. Atherosclerosis 2011;216:258-65.

REGN727: LDL CHOLESTEROL REDUCTION

Phase 3

Change in Calculated LDL-C at Bi-Weekly Intervals from Baseline to Week 12 in Patients With Primary Hypercholesterolemia.



Phase 2 data published in The Lancet, Journal of the American College of Cardiology, and NEJM

Significantly reduced mean LDL-C by 40% to 72% over 8 to 12 weeks in patients on stable dose of statins

Most common adverse event was injection site reaction

Mean percentage change in calculated LDL-C from baseline to weeks 2, 4, 6, 8, 10, and 12 in the modified intent-to-treat (mITT) population, by treatment group. Week 12 estimation using LOCF method.

**Data from Phase 2 , dose-ranging study. Patients were on background atorvastatin therapy of 10, 20, or 40 mg. Decrease in LDL-C shown is at week 12.*

REGN727: LDL CHOLESTEROL REDUCTION

Phase 3

Heterozygous Familial Hypercholesterolemia	High Cholesterol at High Cardiovascular Risk	Additional populations/studies
ODYSSEY FH I — N=471, 18 months	ODYSSEY COMBO I — N=306, 12 months	ODYSSEY MONO — N=100, 6 months
ODYSSEY FH II — N=250, 18 months	ODYSSEY COMBO II — N=660, 24 months	ODYSSEY ALTERNATIVE — N=250, 6 months
ODYSSEY HIGH FH — N=105, 18 months		ODYSSEY OPTIONS I — N=350, 6 months
ODYSSEY LONG TERM — N=2,100, 18 months		ODYSSEY OPTIONS II — N=300, 6 months
	ODYSSEY OUTCOMES — N=18,000 (Event Driven)	

SARILUMAB: RHEUMATOID ARTHRITIS

Phase 3

Significant improvements in signs and symptoms of moderate-to-severe RA in patients receiving sarilumab in combination with methotrexate in Phase 2 study.



*p<0.01 versus placebo (only unadjusted p-values <0.01 are considered statistically significant)

Sarilumab is a fully human, high affinity, interleukin-6 receptor (IL-6R) antibody

Positive Phase 2 study in rheumatoid arthritis

Types and incidence of adverse events consistent with those previously reported with IL-6 inhibition

Phase 3 MOBILITY trial fully enrolled
Phase 3 TARGET trial enrolling

Phase 2 REGN668: ASTHMA AND ATOPIC DERMATITIS

REGN668 is a fully human monoclonal antibody that binds IL-4Rα. Targeting the common IL-4Rα subunit allows for dual IL-4/IL-13 cytokine antagonism with a single agent.



IL-4	IL-13
Dominant (some overlapping) functions in :	
• Initiation and drive of T_H2 differentiation • Activation and growth of B cells • Class switching to IgE and IgG1a • Recruitment of eosinophils	• Airway hyper responsiveness (AHR) • Goblet cell hyperplasia • Tissue remodeling • Fibrosis • Regulation of gastrointestinal parasite expulsion

Positive proof of concept data for atopic dermatitis to be submitted for presentation at a medical conference in 2013

Positive proof of concept data for asthma to be submitted for presentation at a medical conference in 2013

Phase 2b initiation in both indications expected mid-year

BROAD ANTIBODY PIPELINE

Therapeutic Focus Legend: Inflammation | Metabolism | Oncology | Ophthalmology | Pain

Phase 1

- **REGN421 (Dll4 Antibody)**
  Advanced malignancies
- **REGN910 (ANG2 Antibody)**
  Advanced malignancies
- **REGN1033 (GDF8 Antibody)**
  Metabolic disorders
- **REGN1400 (ERBB3 Antibody)**
  Advanced malignancies
- **REGN846**
  (undisclosed target)
  Atopic dermatitis
- **REGN1154**
  (undisclosed target)
- **REGN1500**
  (undisclosed target)

Phase 2

- **REGN668 (IL-4R Antibody)**
  Eosinophilic asthma
- **REGN668 (IL-4R Antibody)**
  Atopic dermatitis
- **REGN475* (NGF Antibody)**
  Osteoarthritis

Phase 3

- **REGN727 (PCSK9 Antibody)**
  LDL cholesterol reduction
- **Sarilumab (IL-6R Antibody)**
  Rheumatoid arthritis
- **EYLEA**
  Diabetic macular edema
- **EYLEA**
  Branch Retinal Vein Occlusion

Novel Antibody Technologies in Preclincal Development

Bispecific Antibodies
Long Acting Technologies
Antibody Drug Conjugates

*Remains on clinical hold by the FDA

SANOFI ANTIBODY COLLABORATION

Discovery

$160 million of annual funding through 2017 (plus possible tail period through 2020)

Development

Sanofi funds approximately 100% of clinical development cost*

Current antibodies include:

- **REGN727 (Phase 3)**
- **Sarilumab (Phase 3)**
- **REGN668 (Phase 2)**
- **3 additional in Phase 1**

Commercialization

Regeneron retains 50% of profits in US**

Regeneron retains 35% to 45% of profits ex-US**

Co-promotion rights in US and other major market countries

**100% development funding by Sanofi for all opted-in antibodies except 80% of an antibody's Phase 3 costs incurred after receipt of the first positive results in a Phase 3 trial for that antibody.*

***Regeneron repays Sanofi for 50% of development costs out of profits. Repayment capped in any year at 10% of Regeneron share of total antibody profits*

FINANCIALS



~$585M to $590M*

Year-end 2012 cash and securities

~$590M to $595M*

Year-end 2012 trade receivables

* Unaudited Estimate

THE YEAR AHEAD

COMMERCIAL MILESTONES

- **EYLEA US sales guidance of ~50% growth (i.e. $1.2B to $1.3B)**
- **EYLEA ex-US launch in multiple additional countries**

EXPECTED REGULATORY MILESTONES

- **EYLEA approval in CRVO outside the U.S.**
- **ZALTRAP approval in metastatic colorectal cancer outside the U.S.**

EXPECTED CLINICAL MILESTONES

- **Top-line 1-year Phase 3 EYLEA results in DME by year end**
- **REGN668 Phase 1b data in Atopic Dermatitis to be presented at a medical conference**
- **REGN668 Phase 2a data in Asthma to be presented at a medical conference**
- **Sarilumab additional Phase 3 trials in RA to start**
- **Enrollment updates for REGN727 in hypercholesterolemia**